Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Pembrolizumab actief bij klassiek en endemisch kaposisarcoom
apr 2022 | Bot en wekedelentumoren, Immuuntherapie